Two patients can be given the same diagnosis — “stage 4 lung cancer” — and need completely different treatments. Tumor profiling is the test that explains why. By reading the genetic changes driving a specific tumor, it can reveal a mutation that a targeted drug is designed to switch off, or a marker that predicts whether immunotherapy will work. This is the foundation of precision oncology: treating the biology of the cancer, not only the organ it started in.

What is tumor profiling?

Tumor profiling — also called comprehensive genomic profiling (CGP), molecular profiling or biomarker testing — is a laboratory analysis of the genetic material inside a tumor. Modern next-generation sequencing (NGS) panels examine hundreds of cancer-related genes in a single test, rather than checking one gene at a time.

The report identifies several classes of change at once: single-letter mutations, small insertions and deletions, extra or missing copies of a gene, gene fusions (two genes fused into an abnormal hybrid), and broader signatures such as tumor mutational burden (TMB) and microsatellite instability (MSI), which help predict response to immunotherapy.

How the test works

Most profiling is done on tumor tissue already obtained during a biopsy or surgery — often the archived paraffin block, so a new procedure may not be needed. The sample is sent to a specialised molecular laboratory, sequenced, and interpreted against curated databases of known cancer-driving alterations and the drugs that target them.

When tissue is unavailable, insufficient or the tumor is difficult to biopsy, a liquid biopsy can be used instead: a blood sample analysed for circulating tumor DNA (ctDNA) shed by the cancer. European Society for Medical Oncology (ESMO) guidance treats tissue sequencing as the preferred route in most settings, with ctDNA as a validated alternative when tissue is not feasible. Results typically take around two to three weeks and are usually discussed by a molecular tumor board — oncologists, pathologists and geneticists who translate the report into a treatment recommendation.

What it is used for

In its 2024 recommendations, ESMO advises tumor NGS for patients with advanced non-squamous non-small-cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma and ovarian cancer, and extends the recommendation to advanced breast cancer, GIST, sarcoma, thyroid cancer and cancer of unknown primary. It also recommends profiling wherever tumor-agnostic alterations could be found and matched therapies are accessible.

Profiling is particularly valuable when: standard first-line treatment has stopped working; the primary site is unknown; the cancer is rare; or a patient wants to know whether a clinical trial or a newly approved targeted drug applies to their case.

From gene to drug: tumor-agnostic treatment

The most striking shift precision oncology has produced is tissue-agnostic approval — a drug licensed for a mutation rather than for an organ. Since 2017 the U.S. FDA has granted a series of such approvals across biomarker classes including MSI-high / mismatch-repair-deficient tumors, TMB-high tumors (generally defined as at least 10 mutations per megabase), and NTRK fusions, RET fusions, BRAF V600E mutations and HER2 overexpression.

The response rates in the registration studies illustrate why the biomarker matters so much. In the trials supporting NTRK-fusion approvals, published objective response rates were high — around three-quarters of patients responding in the larotrectinib dataset — across a wide range of tumor types that otherwise had little in common. For TMB-high tumors treated with pembrolizumab, the reported objective response rate was closer to 29%. The lesson is not that one number is better than another, but that without the test, neither group of patients would have been identified at all.

What the outcome data show

Published studies report that broad NGS panels detect a potentially actionable alteration in a substantial share of advanced tumors — figures well above those achieved by small single-gene panels — and that patients whose treatment is matched to those findings tend to have longer progression-free survival than those receiving unmatched standard therapy. Timing appears to matter as well: in one academic-centre series, patients profiled at diagnosis reached a median overall survival of roughly 18 months, compared with about 14 months among those profiled only after their disease had progressed on standard treatment.

Important caveats apply. Not every actionable finding leads to an available drug, benefit varies considerably by tumor type, and results from selected study populations do not translate directly to individual patients. Profiling widens the options; it does not guarantee an outcome.

The benefits at a glance

• Targeted, not generic — treatment matched to the mutations actually driving the tumor
• Often no new procedure — existing biopsy tissue can usually be used; a blood-based liquid biopsy is the alternative
• Predicts immunotherapy response — TMB and MSI status help identify who is likely to benefit
• Avoids futile treatment — can rule out drugs unlikely to work, sparing time and toxicity
• Opens trial access — many clinical trials now recruit by biomarker rather than by tumor site
• Useful in rare and unknown-primary cancers — where conventional pathways offer little guidance

What to expect

You will be asked to provide either archived tumor tissue or a fresh sample, or to give a blood sample for a liquid biopsy. Sequencing and interpretation usually take two to three weeks. The report is then reviewed by specialists, who explain which alterations were found, whether an approved targeted or immune therapy matches them, and whether any clinical trial is relevant. Some reports also flag inherited (germline) findings, which may have implications for family members — this is discussed with genetic counselling before any testing that could reveal them.

Accessing tumor profiling with Medical E-Aid

Comprehensive profiling is only as useful as the team reading it. Medical E-Aid coordinates access to internationally accredited laboratories and to oncology centres with established molecular tumor boards, so that a genomic report becomes an actual treatment plan rather than a document. We help arrange sample logistics and transport, obtain a specialist review and a transparent cost estimate, and support the practical side of the journey — travel, visas, interpretation and follow-up. Our AI pre-screening helps match each case to the centres best equipped for that specific tumor type.

This article is for general information only and is not medical advice. Testing and treatment suitability depend on each patient’s diagnosis and must be determined by qualified specialists. Outcome figures are drawn from published clinical studies and may not reflect individual results.

Sources: National Cancer Institute (NCI), biomarker and genomic testing resources; ESMO Precision Medicine Working Group, Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer (2024); reviews of tissue-agnostic FDA approvals in solid tumors, PubMed Central (2023–2025); Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers, PMC (2023).